Wellbutrin Users Seek To Revive Class Cert. Bid
Wellbutrin SR users who say GlaxoSmithKline PLC used sham patent litigation to avoid competition have asked a federal court to clarify whether they can refile a previously denied motion for class...To view the full article, register now.
Already a subscriber? Click here to view full article